Financial Incentives to Increase Colorectal Cancer Screening Uptake and Decrease Disparities: A Randomized Clinical Trial.
Attitude to Health
Colonoscopy
/ statistics & numerical data
Colorectal Neoplasms
/ diagnosis
Demography
Early Detection of Cancer
/ economics
Female
Financial Support
Healthcare Disparities
Humans
Male
Middle Aged
Motivation
Occult Blood
Postal Service
/ methods
Socioeconomic Factors
Surveys and Questionnaires
Washington
/ epidemiology
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
03 07 2019
03 07 2019
Historique:
entrez:
6
7
2019
pubmed:
6
7
2019
medline:
13
6
2020
Statut:
epublish
Résumé
Colorectal cancer screening rates are suboptimal, particularly among sociodemographically disadvantaged groups. To examine whether guaranteed money or probabilistic lottery financial incentives conditional on completion of colorectal cancer screening increase screening uptake, particularly among groups with lower screening rates. This parallel, 3-arm randomized clinical trial was conducted from March 13, 2017, through April 12, 2018, at 21 medical centers in an integrated health care system in western Washington. A total of 838 age-eligible patients overdue for colorectal cancer screening who completed a questionnaire that confirmed eligibility and included sociodemographic and psychosocial questions were enrolled. Interventions were (1) mail only (n = 284; up to 3 mailings that included information on the importance of colorectal cancer screening and screening test choices, a fecal immunochemical test [FIT], and a reminder letter if necessary), (2) mail and monetary (n = 270; mailings plus guaranteed $10 on screening completion), or (3) mail and lottery (n = 284; mailings plus a 1 in 10 chance of receiving $50 on screening completion). The primary outcome was completion of any colorectal cancer screening within 6 months of randomization. Secondary outcomes were FIT or colonoscopy completion within 6 months of randomization. Intervention effects were compared across sociodemographic subgroups and self-reported psychosocial measures. A total of 838 participants (mean [SD] age, 59.7 [7.2] years; 546 [65.2%] female; 433 [52.2%] white race and 101 [12.1%] Hispanic ethnicity) were included in the study. Completion of any colorectal screening was not significantly higher for the mail and monetary group (207 of 270 [76.7%]) or the mail and lottery group (212 of 284 [74.6%]) than for the mail only group (203 of 284 [71.5%]) (P = .11). For FIT completion, interventions had a statistically significant effect (P = .04), with a net increase of 7.7% (95% CI, 0.3%-15.1%) in the mail and monetary group and 7.1% (95% CI, -0.2% to 14.3%) in the mail and lottery group compared with the mail only group. For patients with Medicaid insurance, the net increase compared with mail only in FIT completion for the mail and monetary or the mail and lottery group was 37.7% (95% CI, 11.0%-64.3%) (34.2% for the mail and monetary group and 40.4% for the mail and lottery group) compared with a net increase of only 5.6% (95% CI, -0.9% to 12.2%) among those not Medicaid insured (test for interaction P = .03). Financial incentives increased FIT uptake but not overall colorectal cancer screening. Financial incentives may decrease screening disparities among some sociodemographically disadvantaged groups. ClinicalTrials.gov identifier: NCT00697047.
Identifiants
pubmed: 31276178
pii: 2737310
doi: 10.1001/jamanetworkopen.2019.6570
pmc: PMC6789432
mid: NIHMS1047899
doi:
Banques de données
ClinicalTrials.gov
['NCT00697047']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e196570Subventions
Organisme : HSRD VA
ID : IK2 HX001517
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA121125
Pays : United States
Références
JAMA Intern Med. 2018 Dec 1;178(12):1645-1658
pubmed: 30326005
Cancer. 2018 Nov 1;124(21):4145-4153
pubmed: 30359473
Prev Med. 2018 Jul;112:199-206
pubmed: 29729288
Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1047-1056
pubmed: 29891726
Ann Intern Med. 2014 Nov 18;161(10 Suppl):S35-43
pubmed: 25402401
Gastroenterology. 2017 Nov;153(5):1227-1229.e2
pubmed: 28734830
Trends Cogn Sci. 2014 Jun;18(6):293-9
pubmed: 24630971
J Cancer Educ. 2014 Mar;29(1):86-90
pubmed: 24057692
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Ann Intern Med. 2013 Mar 5;158(5 Pt 1):301-11
pubmed: 23460053
Am J Gastroenterol. 2016 Nov;111(11):1630-1636
pubmed: 27481306
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2295-302
pubmed: 24057575
Ann Behav Med. 2010 Oct;40(2):205-17
pubmed: 20658212
J Health Psychol. 2014 Nov;19(11):1443-58
pubmed: 23864072
Am J Prev Med. 2012 Jul;43(1):97-118
pubmed: 22704754
J Am Board Fam Med. 2016 Mar-Apr;29(2):191-200
pubmed: 26957375
BMC Public Health. 2017 May 30;17(1):531
pubmed: 28558663
Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):898-905
pubmed: 15184243
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2231-7
pubmed: 18768488
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2855-61
pubmed: 16365000
Am J Prev Med. 2008 May;34(5):382-8
pubmed: 18407004
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3279-83
pubmed: 18990772
JAMA Netw Open. 2019 Mar 1;2(3):e191156
pubmed: 30901053
Trials. 2010 Mar 24;11:32
pubmed: 20334632
J Gen Intern Med. 2008 May;23(5):561-6
pubmed: 18335281
Cancer. 2015 Dec 1;121(23):4258-65
pubmed: 26308967
MMWR Morb Mortal Wkly Rep. 2017 Mar 03;66(8):201-206
pubmed: 28253225
Am J Public Health. 2014 Jun;104(6):982-6
pubmed: 24825195